Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3

Title: Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3
Authors: Clamp, AR; Lorusso, D; Oza, AM; Aghajanian, C; Oaknin, A; Dean, A; Colombo, N; Weberpals, JI; Scambia, G; Leary, A; Holloway, RW; Amenedo Gancedo, M; Fong, PC; Goh, JC; O'Malley, DM; Armstrong, DK; Banerjee, S; García-Donas, J; Swisher, EM; Cameron, T; Goble, S; Coleman, RL; Ledermann, JA
Source: International Journal of Gynecological Cancer (2021) (In press).
Publication Year: 2021
Collection: University College London: UCL Discovery
Description: INTRODUCTION: In ARIEL3 (NCT01968213), the poly(adenosine diphosphate-ribose) polymerase inhibitor rucaparib significantly improved progression-free survival versus placebo regardless of biomarker status when used as maintenance treatment for recurrent ovarian cancer. The aim of the current analyses was to evaluate the efficacy and safety of rucaparib in subgroups based on progression-free interval following penultimate platinum, number of prior chemotherapies, and prior use of bevacizumab. METHODS: Patients were randomized 2:1 to rucaparib 600 mg twice daily or placebo. Within subgroups, progression-free survival was assessed in prespecified, nested cohorts: BRCA-mutant, homologous recombination deficient (BRCA-mutant or wild-type BRCA/high genomic loss of heterozygosity), and the intent-to-treat population. RESULTS: In the intent-to-treat population, median investigator-assessed progression-free survival was 8.2 months with rucaparib versus 4.1 months with placebo (n=151 vs n=76; HR 0.33, 95% CI 0.24 to 0.46, p
Document Type: article in journal/newspaper
File Description: text
Language: English
Relation: https://discovery.ucl.ac.uk/id/eprint/10130249/3/Ledermann_ARIEL3_Clamp%20Lorusso_Prior%20therapies%20PFI_Draft_12Apr_main%20document.pdf; https://discovery.ucl.ac.uk/id/eprint/10130249/
Availability: https://discovery.ucl.ac.uk/id/eprint/10130249/3/Ledermann_ARIEL3_Clamp%20Lorusso_Prior%20therapies%20PFI_Draft_12Apr_main%20document.pdf; https://discovery.ucl.ac.uk/id/eprint/10130249/
Rights: open
Accession Number: edsbas.CC15B710
Database: BASE